NCT02935361View on ClinicalTrials.gov

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 2, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions
DRUG

Atezolizumab

Given IV

DRUG

Guadecitabine

Given SC

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

19140

Temple University Hospital, Philadelphia

21201

University of Maryland Medical Center, Baltimore

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Van Andel Research Institute

OTHER

lead

University of Southern California

OTHER

NCT02935361 - Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | Biotech Hunter | Biotech Hunter